Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.60 |
| ▸ | AR | P10275 | 4/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295805 | 0.82 | PGR (0.60) | PGRARNR3C1NR3C2 | |
| SCHEMBL3382295 | 0.81 | PGR (0.43) | PGRARNR3C1NR3C2 | |
| SCHEMBL3382066 | 0.81 | PGR (0.43) | PGRARNR3C1NR3C2 | |
| SCHEMBL3876801 | 0.81 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL61925 | 0.81 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| Brofoxine SCHEMBL29710912 | 0.81 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL12649317 | 0.81 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL3380231 | 0.81 | PGR (0.59) | PGRARNR3C1NR3C2 | |
| SCHEMBL10531285 | 0.80 | ELOVL6 (0.42) | PGRARNR3C1NR3C2 | |
| SCHEMBL9598945 | 0.80 | PGR (0.50) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7354915-B2 | 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1844768-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH | 2005-04-21 | — | — | US | disclosed |
| US-4831027-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1989-05-16 | — | — | US | disclosed |
| EP-0263352-A1 | Imidazo-benzoxazinones, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160304-A1 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR | NR3C2, AGTR1, AGTR2 | PGR 288/4885AR 17/4885NR3C1 9/4885 |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | PGR 1/4885AR 109/4885NR3C1 11/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | PGR 1/4885AR 109/4885NR3C1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.